Country: Malta
Language: English
Source: Medicines Authority
everolimus 0.1 mg
Novartis Pharmaceuticals UK Limited
L04AA18
everolimus
dispersible tablet
Authorised
2009-04-21
PACKAGE LEAFLET: INFORMATION FOR THE USER CERTICAN 0.1 MG DISPERSIBLE TABLETS CERTICAN 0.25 MG DISPERSIBLE TABLETS Everolimus READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Certican is and what it is used for 2. What you need to know before you take Certican 3. How to take Certican 4. Possible side effects 5. How to store Certican 6. Contents of the pack and other information 1. WHAT CERTICAN IS AND WHAT IT IS USED FOR The active substance of Certican is everolimus. Everolimus belongs to a group of medicines called immunosuppressants. It is used to prevent the body’s immune system from rejecting a transplanted kidney, heart or liver. Certican is used together with other medicines, such as ciclosporin for kidney and heart transplantation, tacrolimus for liver transplantation, and corticosteroids. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CERTICAN DO NOT TAKE CERTICAN • if you are allergic (hypersensitive) to everolimus or any of the other ingredients of Certican listed in section 6 of this leaflet. • if you are allergic (hypersensitive) to sirolimus. IF ANY OF THE ABOVE APPLIES TO YOU, TELL YOUR DOCTOR AND DO NOT TAKE CERTICAN. WARNINGS AND PRECAUTIONS Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Certican 0.1 mg dispersible tablets Certican 0.25 mg dispersible tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dispersible tablet contains 0.1 / 0.25 mg everolimus. Each dispersible tablet contains 1 / 2 mg lactose monohydrate and 72 / 179 mg anhydrous lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Dispersible tablet Dispersible tablets are white to yellowish, marbled, round, flat with a bevelled edge. 0.1 mg: engraved with “I” on one side and “NVR” on the other. 0.25 mg: engraved with “JO” on one side and “NVR” on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Kidney and heart transplantation Certican is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk_ _receiving an allogeneic renal or cardiac transplant. In kidney and heart transplantation, Certican should be used in combination with ciclosporin for microemulsion and corticosteroids. Liver transplantation Certican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. In liver transplantation, Certican should be used in combination with tacrolimus and corticosteroids. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Certican should only be initiated and maintained by physicians who are experienced in immunosuppressive therapy following organ transplantation and who have access to everolimus whole blood levels monitoring. Posology _Adults _ An initial dose regimen of 0.75 mg twice daily is recommended for the general kidney and heart transplant population, administered as soon as possible after transplantation. The dose of 1.0 mg twice dai Read the complete document